{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:02:51Z","timestamp":1769086971291,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022965","name":"Colombia Ministry of Science Technology and Innovation","doi-asserted-by":"publisher","award":["731\\u20132023"],"award-info":[{"award-number":["731\\u20132023"]}],"id":[{"id":"10.13039\/100022965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127724","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:48:17Z","timestamp":1757494097000},"page":"127724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Validation and evaluation of the rapid fluorescent focus inhibition test (RFFIT) for the quantification of neutralizing antibodies as an indirect measure of rabies vaccine relative potency: An alternative to the NIH test"],"prefix":"10.1016","volume":"64","author":[{"given":"Sara S.","family":"Tibavija","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda P.","family":"Almario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Yanira","family":"Chaparro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"Paramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Ladino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulma Roc\u00edo","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127724_bb0005","series-title":"\u201cRabies,\u201d World Health Organization","volume":"15","author":"Jordan","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127724_bb0010","unstructured":"World Health Organization (WHO) Requirements for rabies vaccine for human use. Requirements for biological substances No.22Annex 2007. 2, TRS No 658 Pages 54-89."},{"issue":"2","key":"10.1016\/j.vaccine.2025.127724_bb0015","first-page":"37","article-title":"Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use","volume":"2010","author":"Kr\u00e4mer","year":"2010","journal-title":"Pharmeur Bio Sci Notes"},{"key":"10.1016\/j.vaccine.2025.127724_bb0020","series-title":"Annex 2 Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs","author":"World Health Organization (WHO)","year":"2007"},{"key":"10.1016\/j.vaccine.2025.127724_bb0025","series-title":"WHO TRS N\u00b01012","author":"WHO Expert Consultation on Rabies","year":"2018"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127724_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000595","article-title":"Rabies-specific antibodies: measuring surrogates of protection against a fatal disease","volume":"4","author":"Moore","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127724_bb0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biologicals.2016.09.007","article-title":"Rabies vaccine response measurement is assay dependent","volume":"44","author":"Moore","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2025.127724_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.06.017","article-title":"Rapid fluorescent focus inhibition test optimization and validation: improved detection of neutralizing antibodies to rabies virus","volume":"474","author":"Timiryasova","year":"2019","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127724_bb0045","doi-asserted-by":"crossref","first-page":"26793","DOI":"10.1038\/s41598-024-77331-8","article-title":"Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects","volume":"14","author":"Doroud","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127724_bb0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(88)90185-5","article-title":"NIH test, a problematic mehtod for testing potency of inactivated rabies vaccine","volume":"6","author":"Barth","year":"1988","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127724_bb0055","series-title":"Laboratory techniques in rabies, fifth., vol. 1. World health","author":"Rupprecht","year":"2018"},{"key":"10.1016\/j.vaccine.2025.127724_bb0060","series-title":"United states pharmacopeia","article-title":"Validation of Compendial Procedures","author":"United States Pharmacopeia","year":"2024"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127724_bb0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127724_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1198","article-title":"Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach","volume":"12","author":"Akter","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127724_bb0075","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127724_bb0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jviromet.2009.05.018","article-title":"Development and evaluation of a rapid neutralizing antibody test for rabies","volume":"161","author":"Shiota","year":"2009","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2025.127724_bb0085","series-title":"The immunological basis for immunization series: module 17: rabies vaccine (Immunological basis for immunization series\u00a0; module 17)","author":"World Health Organization","year":"2017"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127724_bb0090","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/vim.2019.0131","article-title":"Possibility of immediate introduction of a single-dose antibody induction test as a refinement of the NIH test for inactivated rabies vaccine potency determination","volume":"33","author":"Stankov","year":"2020","journal-title":"Viral Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127724_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/026119291504300106","article-title":"A step forward in the quality control testing of inactivated rabies vaccines \u2014 extensive evaluation of European vaccines by using alternative methods to the in vivo potency tests","volume":"43","author":"Servat","year":"2015","journal-title":"Altern Lab Anim"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127724_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biologicals.2009.01.001","article-title":"The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines","volume":"37","author":"Kr\u00e4mer","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2025.127724_bb0105","series-title":"Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research, Q2(R2): Validation of Analytical Procedures \u2013 Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127724_bb0110","series-title":"Guideline on bioanalytical method validation","author":"European Medicines Agency (EMA)","year":"2011"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127724_bb0115","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1128\/AAC.06179-11","article-title":"Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples","volume":"56","author":"Kostense","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2025.127724_bb0120","series-title":"EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127724_bb0125","first-page":"307","article-title":"Inestabilidad de muestras obtenidas durante la hidrodesintegraci\u00f3n de residuos del petr\u00f3leo [Instability of samples obtained during hydrodisintegration of petroleum residues]","volume":"47","author":"G\u00f3mez","year":"2003","journal-title":"Revista de la Sociedad Qu\u00edmica de M\u00e9xico"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127724_bb0130","doi-asserted-by":"crossref","first-page":"218","DOI":"10.17221\/5827-VETMED","article-title":"Comparison of the detection and quantification of rabies antibodies in canine sera","volume":"47","author":"Ondrejkov\u00e1","year":"2002","journal-title":"Vet Med (Praha)"},{"key":"10.1016\/j.vaccine.2025.127724_bb0135","series-title":"Guidance for industry: Bioanalytical method validation","author":"U.S. Department of Health and Human Services","year":"2001"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2025.127724_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10616-006-9009-4","article-title":"Introduction to animal cell culture technology\u2014past, present, and future","volume":"50","author":"Merten","year":"2006","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2025.127724_bb0145","first-page":"1","article-title":"The mechanisms of coronavirus entry into cells","volume":"66","author":"Chu","year":"2005","journal-title":"Adv Virus Res"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127724_bb0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/154065804322966315","article-title":"Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays","volume":"2","author":"Riss","year":"2004","journal-title":"Assay Drug Dev Technol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127724_bb0155","doi-asserted-by":"crossref","first-page":"9893","DOI":"10.1038\/s41598-020-66754-8","article-title":"Preparation and qualification of internal rabies reference standards for use in the rabies rapid fluorescent focus inhibition test","volume":"10","author":"Timiryasova","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127724_bb0160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jviromet.2018.10.003","article-title":"Development and pre-validation of a quantitative multi-dose serological assay for potency testing of inactivated rabies vaccines for human use","volume":"263","author":"Moreira","year":"2019","journal-title":"J Virol Methods"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127724_bb0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12250-012-3260-y","article-title":"A semi-quantitative serological method to assess the potency of inactivated rabies vaccine for veterinary use","volume":"27","author":"Liu","year":"2012","journal-title":"Virol Sin"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127724_bb0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/vim.2021.0181","article-title":"Evaluation and correlation of rabies vaccine potency using the National Institute of health, rapid focus fluorescent inhibition, and passive Hemagglutination tests","volume":"35","author":"Khalil","year":"2022","journal-title":"Viral Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127724_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006084","article-title":"Development and evaluation of an anti-rabies virus phosphoprotein-specific monoclonal antibody for detection of rabies neutralizing antibodies using RFFIT","volume":"11","author":"Um","year":"2017","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:53:29Z","timestamp":1769025209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25010217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"alternative-id":["S0264410X25010217"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127724","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation and evaluation of the rapid fluorescent focus inhibition test (RFFIT) for the quantification of neutralizing antibodies as an indirect measure of rabies vaccine relative potency: An alternative to the NIH test","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127724"}}